Valproic acid is named as an intervention in 4 current clinical trials in our Italy, Spain, Netherlands and Norway registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute, Naples (2). The most-studied condition is Adenocarcinoma of the Pancreas.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Seizure Treatment in Glioma
NCT03048084 · ClinicalTrials.gov ↗ · Glioma
|
Phase 4 | Recruiting | Leiden University Medical Center | Netherlands |
|
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
NCT05821556 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Pancreas
|
Phase 2 | Recruiting | National Cancer Institute, Naples | Spain, Italy |
|
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
NCT06714357 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
|
Phase 2 | Recruiting | National Cancer Institute, Naples | Italy |
|
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
NCT06199557 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult
|
Phase 1/2 | Recruiting | Haukeland University Hospital | Norway |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute, Naples | 2 |
| Leiden University Medical Center | 1 |
| Haukeland University Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 2 | 2 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Norway | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our Italy, Spain, Netherlands and Norway registers name Valproic acid as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 2 with sites in Italy, 1 with sites in Spain, 1 with sites in Netherlands and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
National Cancer Institute, Naples (2), Leiden University Medical Center (1) and Haukeland University Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Valproic acid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Valproic acid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Valproic acid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.